Your browser doesn't support javascript.
loading
Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse model.
Marchal, Gerard A; van Putten, Maaike; Verkerk, Arie O; Casini, Simona; Putker, Kayleigh; van Amersfoorth, Shirley C M; Aartsma-Rus, Annemieke; Lodder, Elisabeth M; Remme, Carol Ann.
Afiliación
  • Marchal GA; Department of Experimental Cardiology, Amsterdam UMC (Location AMC), Meibergdreef 9, 1005 AZ, Amsterdam, The Netherlands. g.a.marchal@amsterdamumc.nl.
  • van Putten M; Department of Human Genetics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
  • Verkerk AO; Department of Experimental Cardiology, Amsterdam UMC (Location AMC), Meibergdreef 9, 1005 AZ, Amsterdam, The Netherlands.
  • Casini S; Amsterdam UMC (Location AMC), Department of Medical Biology, Meibergdreef 9, 1005 AZ, Amsterdam, The Netherlands.
  • Putker K; Department of Experimental Cardiology, Amsterdam UMC (Location AMC), Meibergdreef 9, 1005 AZ, Amsterdam, The Netherlands.
  • van Amersfoorth SCM; Department of Human Genetics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
  • Aartsma-Rus A; Department of Experimental Cardiology, Amsterdam UMC (Location AMC), Meibergdreef 9, 1005 AZ, Amsterdam, The Netherlands.
  • Lodder EM; Department of Human Genetics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
  • Remme CA; Department of Experimental Cardiology, Amsterdam UMC (Location AMC), Meibergdreef 9, 1005 AZ, Amsterdam, The Netherlands.
Sci Rep ; 11(1): 9779, 2021 05 07.
Article en En | MEDLINE | ID: mdl-33963238
Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder caused by loss of dystrophin. This lack also affects cardiac structure and function, and cardiovascular complications are a major cause of death in DMD. Newly developed therapies partially restore dystrophin expression. It is unclear whether this will be sufficient to prevent or ameliorate cardiac involvement in DMD. We here establish the cardiac electrophysiological and structural phenotype in young (2-3 months) and aged (6-13 months) dystrophin-deficient mdx mice expressing 100% human dystrophin (hDMD), 0% human dystrophin (hDMDdel52-null) or low levels (~ 5%) of human dystrophin (hDMDdel52-low). Compared to hDMD, young and aged hDMDdel52-null mice displayed conduction slowing and repolarisation abnormalities, while only aged hDMDdel52-null mice displayed increased myocardial fibrosis. Moreover, ventricular cardiomyocytes from young hDMDdel52-null animals displayed decreased sodium current and action potential (AP) upstroke velocity, and prolonged AP duration at 20% and 50% of repolarisation. Hence, cardiac electrical remodelling in hDMDdel52-null mice preceded development of structural alterations. In contrast to hDMDdel52-null, hDMDdel52-low mice showed similar electrophysiological and structural characteristics as hDMD, indicating prevention of the cardiac DMD phenotype by low levels of human dystrophin. Our findings are potentially relevant for the development of therapeutic strategies aimed at restoring dystrophin expression in DMD.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Distrofina / Distrofia Muscular de Duchenne / Miocitos Cardíacos / Electrofisiología Cardíaca / Miocardio Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Distrofina / Distrofia Muscular de Duchenne / Miocitos Cardíacos / Electrofisiología Cardíaca / Miocardio Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido